Ipca Laboratories

What Ipca Laboratories does

Ipca Laboratories Ltd., founded in 1949 and headquartered in Mumbai, is a vertically integrated Indian pharmaceutical company manufacturing over 80 Active Pharmaceutical Ingredients (APIs) at 12 production facilities and 350+ formulations across oral solids, powder for suspensions, and small volume injectables. Its technology base rests on backward integration from chemical synthesis through finished dosage forms, with leadership positions in 12+ APIs globally across cardiovascular (Atenolol, Metoprolol, Losartan, Propranolol), anti-malarial (Chloroquine Phosphate, Hydroxychloroquine Sulphate), diuretic (Furosemide, Chlorthalidone), and anthelmintic (Pyrantel Salts) categories. Four dedicated facilities are accredited by UK-MHRA, EDQM-Europe, WHO-Geneva, Health Canada, TGA-Australia, and SAHPRA-South Africa, enabling market access in the most stringent regulated geographies. In June 2026, the company licensed Bhami Research Laboratories' high-concentration subcutaneous biologics platform to begin developing monoclonal antibodies in oncology and inflammatory disease, marking a modality expansion beyond small molecules.

The company operates a dual-track go-to-market model: domestic Indian formulations are sold via field sales into India's pharmaceutical distribution network (5 brands among the top 300 of the IPM per IQVIA Oct 2023, spanning Pain, Rheumatology, Antimalarials, and Hair care), while international business is executed through dossier out-licensing, contract manufacturing, and CRAMS partnerships across 120+ countries in six continents. It has supplemented indirect export channels with directly owned front-end operations in the USA via Bayshore Pharmaceuticals and in the UK under the Ipca label. The Unichem subsidiary is being re-engineered for higher margin via an Ireland-to-India production shift expected to deliver ₹40–50 crore of annual savings and lift Unichem EBITDA margin to 12–13% in FY27.

Revenue is split across three streams — APIs (≈25% of turnover), domestic formulations (≈40%, the largest EBITDA contributor at ~55% of consolidated EBITDA), and international formulations (≈40%, growing 9% YoY in Q4FY26). FY26 consolidated revenue reached ₹9,646 crore (up 8% YoY) with EBITDA margin expanding to 20.5% from 19.3%; FY27 EBITDA margin guidance is 22–23%. Other subsidiaries include Trophic Wellness (52.35% stake, nutraceuticals) and the pending Krebs Biochemicals amalgamation (fermentation-based APIs). The combined platform produces 18–20 planned new launches in FY27 across the US, Europe, and emerging markets.

Name

Ipca Laboratories

Legal name

Ipca Laboratories Ltd.

Website

https://ipcalabs.com

Company type

Public

Founded year

1949

Operating status

Operating

Headcount range

5,001–10,000 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

akta.pro secondary industry

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Pharmaceutical manufacturing
• Active pharmaceutical ingredients
• Generic formulations
• API manufacturing
• Contract manufacturing services

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Domestic Formulations: Sale of branded and generic pharmaceutical formulations within India, covering therapeutic segments including Pain, Rheumatology, Antimalarials, and Hair care. Domestic formulations contributed significantly with 12% YoY growth in Q4FY26 and revenue of ₹853.33 crore, representing approximately 40% of consolidated revenues and 55% of EBITDA.
2. International/Export Formulations: Sale of generic formulations to international markets including North America, Europe, UK, Australia, and South Africa through various business models — dossier out-licensing, contract manufacturing, and CRAMS partnerships. Exports grew 9% year-on-year to ₹845.53 crore in Q4FY26.
3. Active Pharmaceutical Ingredients (APIs): Production and sale of over 80 APIs from 12 production facilities, accounting for approximately 25% of Ipca's total turnover. APIs are exported to over 70 countries globally, serving as one of India's top API exporters with leadership positions in more than 12 APIs worldwide.
4. Contract Manufacturing & CRAMS: Business Development team collaborates with partners across continents establishing product presence through dossier out-licensing, contract manufacturing, and Contract Research and Manufacturing Services (CRAMS) in regulated markets.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels4 records

Core offering

Ipca Laboratories is a fully-integrated pharmaceutical company that manufactures over 350 branded and generic formulations and over 80 Active Pharmaceutical Ingredients (APIs) across therapeutic segments including Pain, Rheumatology, Antimalarials, Hypertension, Heart Failure, and Hair care. The company operates 15 API and 11 formulations manufacturing facilities approved by stringent regulatory bodies (UK-MHRA, EDQM-Europe, WHO-Geneva, Health Canada, TGA-Australia, SAHPRA-South Africa) and sells its products in over 120 countries globally.

Product overview

Ipca Laboratories is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. The company operates a platform-plus-products architecture with core offerings in Active Pharmaceutical Ingredients (APIs) and Generic Formulations, supported by international operations through acquired brands like Bayshore Pharmaceuticals (USA) and direct Ipca label operations (UK). Manufacturing leadership spans cardiovascular, anti-malarial, pain management, rheumatology, and hair care therapies, with facilities approved by major regulatory bodies including UK-MHRA, EDQM-Europe, and WHO-Geneva.

Differentiator

Problem solved

Functional benefit

Brands

• ACNE-UV Gel: Therapeutic sunscreen product with advanced sun protection for human and aquatic safety, for which Ipca secured a GUINNESS WORLD RECORDS title

Products and services

• Active Pharmaceutical Ingredients (APIs) Over 80 APIs produced from scratch through backward integration at 12 production facilities, accounting for nearly 25% of turnover. Key APIs serve cardiovascular, anti-malarial, diuretic, and anthelmintic therapeutic applications, exported to pharmaceutical manufacturers in over 70 countries.
• Generic Formulations Portfolio of 350+ formulations across therapeutic segments including Pain, Rheumatology, Antimalarials, Hypertension, Heart Failure, and Hair care in dosage forms including oral solids, powder for suspension, and small volume injections. Manufacturing facilities accredited by Health Canada, MHRA-UK, TGA-Australia, SAHPRA-South Africa, and WHO-Geneva.
• ACNE-UV Gel Therapeutic Sunscreen Therapeutic sunscreen product with advanced sun protection for human and aquatic safety, for which Ipca secured a Guinness World Records title. Sample cartons were distributed to Government Hospitals in Mumbai.
• Contract Manufacturing & CRAMS Services Contract Research and Manufacturing Services (CRAMS) and contract manufacturing for international partners across regulated markets, including dossier out-licensing, product manufacturing, and research collaborations.

Quantifiable outcome

• FY26 revenue of ₹9,646 crore, up 8% year-on-year, with EBITDA margin expanding to 20.5% from 19.3% in FY25
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Krebs Biochemicals & Industries LtdcoreStrategic or Co-development Partner · 26 June 2026The board of directors of Krebs Biochemicals & Industries Ltd approved an amalgamation scheme with Ipca Laboratories on June 26, 2026, involving a share exchange ratio of 7 Ipca shares for every 200 Krebs shares. The merger aims to secure fermentation-based active pharmaceutical ingredient (API) supply and intermediates while creating operational synergies to ensure uninterrupted supply of critical materials. The combined entity is expected to leverage complementary strengths including IPCA Labs' global distribution network and Krebs Biochemicals' expertise in fermentation-based APIs.
• Bhami Research Laboratories (BRL)coreTechnology or Integration · 13 June 2026Ipca Laboratories signed a global licensing agreement with Mangalore-headquartered Bhami Research Laboratories for access to BRL's proprietary high-concentration subcutaneous biologics delivery platform to develop monoclonal antibody products targeting oncology and inflammatory diseases. Ipca will undertake R&D, clinical trials, and commercial manufacturing while BRL provides its delivery platform technology. BRL will receive milestone fees and earn royalties on net sales upon commercialization. The collaboration aims to accelerate development of affordable biologics for cancer and autoimmune disease patients worldwide.
• Trophic Wellness Pvt LtdminorStrategic or Co-development Partner · 12 June 2021Ipca Laboratories increased its stake in Trophic Wellness to 52.35% through a cash acquisition of 13.09% of its shares, making Trophic Wellness a subsidiary. The acquisition valued at Rs. 21.20 crores aims to expand Ipca's nutraceuticals portfolio. Prior to this acquisition, Ipca held approximately 39.26% stake in Trophic Wellness.

Scale indicators20 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Cipla: Cipla is one of India's largest generic pharmaceutical manufacturers with a similar integrated API + formulations model, strong export presence across regulated markets, and overlapping therapeutic focus in respiratory, cardiovascular, and anti-infectives — making it the closest direct peer to Ipca.
• Sun Pharmaceutical Industries: Sun Pharma is India's largest pharma company with a vertically integrated API-to-formulations model, dominant US generic presence, and similar backward integration strategy — directly comparable to Ipca on scale, business model, and global market access.
• Dr. Reddy's Laboratories: Dr. Reddy's is a leading Indian pharma with strong API manufacturing capabilities, US generics franchise, and a portfolio spanning cardiovascular, dermatology, and oncology — directly comparable to Ipca on integration model and therapeutic coverage.
• Lupin Limited: Lupin is a major Indian generic pharma with significant API manufacturing operations, strong US presence, and focus on cardiovascular, anti-infectives, and CNS — a direct peer in business model, therapeutic areas, and global regulatory strategy.
• Aurobindo Pharma: Aurobindo is among India's top API manufacturers and generic formulations exporters with strong US and EU presence, directly comparable to Ipca in API leadership, vertically integrated operations, and emerging markets expansion.
• Zydus Lifesciences (Cadila Healthcare): Zydus is an integrated Indian pharma with API manufacturing, formulations, biologics, and consumer wellness businesses — closely matching Ipca's diversified portfolio and its recent move into biologics via the Bhami partnership.
• Torrent Pharmaceuticals: Torrent Pharma is an Indian pharma with focus on cardiovascular, CNS, and gastroenterology therapeutic segments plus strong API capabilities — comparable to Ipca on therapeutic focus, integration model, and emerging markets presence.
• Glenmark Pharmaceuticals: Glenmark is an India-based generic and specialty pharma with API manufacturing, formulations, and emerging biologics pipeline — comparable to Ipca in therapeutic diversification, US/India dual market strategy, and recent innovation pivots.

Broad incumbents

• Teva Pharmaceutical Industries: Teva is the world's largest generic drug manufacturer with broad API and finished dosage capabilities across virtually every therapeutic area — a broad incumbent that competes with Ipca globally but at much greater scale and with a more diversified portfolio.

Emerging players

• Apotex Inc. Apotex is a Canadian-headquartered generic pharmaceutical manufacturer with vertically integrated API and formulations operations, primarily serving North American markets — a comparable integrated generics player with similar regulatory and therapeutic focus areas as Ipca.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ipca

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries4 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A7 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ipca Laboratories